Michaela Fontenay, MD, PhD, Cochin Hospital, Paris, France, comments on the impact of SF3B1 mutations in myelodysplastic syndromes (MDS), highlighting the potential of targeting DNA replication stress in these patients, and discussing recent advances in treatments for patients with SF3B1-mutant MDS resistant to luspatercept. This interview took place at the 17th International Congress on Myelodysplastic Syndromes 2023 (MDS 2023) held in Marseille, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.